BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Science '22 in Review
Top Biopharma Trends of 2022
Top Med-tech Trends of 2022
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, December 6, 2023
Breaking News: Topic alerts now available for all BioWorld subscribers
See today's BioWorld Science
Home
» Sirpant-M granted US orphan drug designation for T-cell lymphoma
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Immuno-oncology
Sirpant-M granted US orphan drug designation for T-cell lymphoma
Nov. 16, 2023
No Comments
Sirpant Immunotherapeutics Inc.’s lead product candidate, Sirpant-M (SI-101), has been awarded U.S. orphan drug designation for the treatment of T-cell lymphoma.
BioWorld Science
Regulatory
Cell therapy
Cancer
Immuno-oncology
FDA
Orphan drug
